Karyopharm Therapeutics | KPTI - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.63B 54M 2026-06
Abbott USD 3.6B 330M 2026-06
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
GlaxoSmithKline GBP 2.19B 75M 2026-06
Incyte USD 351.73M 23.64M 2026-06
J&J USD 6.42B 381M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.89B 219M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Pfizer USD 3.41B 496M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Takeda JPY 286.51B 5.48B 2026-06
Tectonic Therapeutic USD 6.43M 2.99M 2026-03
TG Therapeutics USD 62.32M 10.82M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Xencor USD 77.54M 4.59M 2026-06